Posted by: Market Watch in Market News 30 minutes in the past Progenics Prescription drugs, Inc. stated Monday a late-stage trial of a ther
Progenics Prescription drugs, Inc. stated Monday a late-stage trial of a therapy for prostate most cancers met its principal aim. The New York-based firm stated the section three trial known as Condor evaluating the diagnostic efficiency of PyL(TM) ((18) F-DCFPyL) in males with biochemical recurrence of prostate most cancers met its major endpoint of bettering the visualization of the illness. The path concerned 208 sufferers at 14 websites within the U.S. and Canada. The corporate is planning to file a brand new drug utility to the U.S. Meals and Drug Administration within the second half of 2020. Shares rose 29% after resuming commerce following a halt for the information. The inventory has gained 23% within the yr by Friday, whereas the S&P 500 has gained 28.5%. Market Pulse Tales are Fast-fire, brief information bursts on shares and markets as they transfer. Go to MarketWatch.com for extra data on this information.
Newest posts by Market Watch (see all)